pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
Placebo de macitentan 10 mg, MACITENTAN
Phase 2 · small molecule · Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology
Placebo de macitentan 10 mg, MACITENTAN for Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP201037
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology
- Status
- active
- Trials
- 1